Treatment of PBMCs from these two MBP-responsive subjects with LPX-TI641 resulted in a dose-dependent reversal of MBP87–99-mediated suppression of both total Tregs and the Tim3+ Treg subset (Figure 10E,F), supporting the potential of LPX-TI641 to restore immune tolerance in MS patients with autoreactive T-cell populations. The gene discussed is HAVCR2; the disease is myeloid sarcoma.